The Roadmap concept: Using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B

Hepatology International

Volumn 2, Issue 3, 2008, Pages 304-307

  Gane, Edward J ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Chronic hepatitis B; Genetic barrier to resistance; On treatment response; PCR nondetectability; Roadmap concept

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CANCER; LIVER CIRRHOSIS; LONG TERM CARE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 51049121362     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9083-0     Document Type: Review

References (17)

1. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
2. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
3. Chen G, Lin W, Shen F, Ileoje UH, London WT, Evans AA. Past HBV viral load as a predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-1803.
4. Yuan HJ, Yuen MF, Wong DK, Sablon E, Lai CL. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J Viral Hepat 2005;12:373-379.
5. Yuen MF, Yuan HJ, Wong DK, Yuen JK, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: Therapeutic implications. Gut 2005;54:1610-1614.
6. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature. Hepatology 2003;37:1309-1319.
7. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791.
8. Liaw YF, Leung N, Kao J-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatology Int 2008 (in press).
9. Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B. Hepatology 2007;45:507-539.
10. EASL international consensus conference on hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement. J Hepatol 2003;38:533-540.
11. Lai C, Gane E, Liaw Y-FMD, Thongsawat S, et al. Telbivudine versus lamivudine for patients with chronic hepatitis B. N Engl J Med 2007;357:34-46.
12. DiBisceglie A, Lai CL, Gane E, et al. Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B (Abstract). Hepatology 2006;44(Suppl 1):230A-231A.
13. Keeffe E, Zeuzem S, Koff R, Dieterich D, Gane E, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-897.
14. Gish R, Lok A, Chang T, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-1444.
15. Hadziyannis S, Tassopoulos N, Heathcote E, et al. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751.
16. Chang T-T, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New Engl J Med 2006;354(10):1001-1010.
17. Heathcote J, Gane E, DeMan R, Lee S, Flisiak R, et al. Tenofovir DF for Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive (+) Chronic Hepatitis B. Boston: AASLD; 2007.